The US Food and drug Administration (FDA) has proposed revisions to the de novo pathway in order to make medical device classification more efficient and transparent.

The De Novo pathway is used to review new, low-to-moderate risk devices and determine predicates that assure certain safety and effectiveness measures.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The regulatory agency have published the new de novo Classification Proposed Rule involving procedures and criteria associated with the process. The rule is intended to enable ‘appropriate’ classification of new types of medical devices.

Specifically, the revision offers structure, clarity and transparency on the format and content of de novo requests, and the processes and requirements for acceptance, declining and withdrawal of the requests.

“The regulatory agency have published the new de novo Classification Proposed Rule involving procedures and criteria associated with the process.”

The move comes shortly after the FDA announced plans to modernise the medical device 510(k) clearance pathway.

FDA commissioner Scott Gottlieb said: “Our goal is to make the de novo pathway significantly more efficient and transparent by clarifying the requirements for submission and our processes for review. As a result, we expect to see more developers take advantage of the de novo pathway for novel devices.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The proposed regulation we’re issuing today-as well as those steps that we announced last week-will help the FDA regulate new technologies in ways that enable us to protect patient safety while promoting innovations that can advance peoples’ health and function.”

The regulatory agency also formally recognised a public database called ClinGen Expert Curated Human Genetic Data, which comprises information on genes, genetic variants and their relationship to disease.

This is expected to enable the development of new, beneficial genetic tests. Developers will be able to use the information in the database to support the validity of their tests, rather than generating data on their own.